VAXCYTE, INC. Research and Development Expense
VAXCYTE, INC. (PCVX) reported Research and Development Expense of $267.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- VAXCYTE, INC. research and development expense for the quarter ending 2026-06-30 was $267.85M, a 37.94% increase year-over-year.
- VAXCYTE, INC. research and development expense for the quarter ending 2026-03-31 was $312.78M, a 111.15% increase year-over-year.
- VAXCYTE, INC. research and development expense for the quarter ending 2025-12-31 was $242.06M, a 81.16% increase year-over-year.
- VAXCYTE, INC. research and development expense for the quarter ending 2025-09-30 was $209.93M, a 79.53% increase year-over-year.
- VAXCYTE, INC. research and development expense for fiscal 2025 was $794.31M, a 66.65% increase from fiscal 2024.
- VAXCYTE, INC. research and development expense for fiscal 2024 was $476.64M, a 43.42% increase from fiscal 2023.
- VAXCYTE, INC. research and development expense for fiscal 2023 was $332.34M, a 96.13% increase from fiscal 2022.
- VAXCYTE, INC. research and development expense for fiscal 2022 was $169.45M, a 116.11% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $267.85M 10-Q · filed 2026-08-05 | $580.63M 10-Q · filed 2026-08-05 | $822.69M derived: sum of 3 quarters · filed 2026-08-05 | $1.03B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $312.78M 10-Q · filed 2026-05-06 | $554.84M derived: sum of 2 quarters · filed 2026-05-06 | $764.77M derived: sum of 3 quarters · filed 2026-05-06 | $958.95M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $242.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $451.99M derived: sum of 2 quarters · filed 2026-02-24 | $646.17M derived: sum of 3 quarters · filed 2026-08-05 | $794.31M 10-K · filed 2026-02-24 |
| 2025-09-30 | $209.93M 10-Q · filed 2025-11-04 | $404.11M derived: sum of 2 quarters · filed 2026-08-05 | $552.25M 10-Q · filed 2025-11-04 | $685.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $194.18M 10-Q · filed 2026-08-05 | $342.31M 10-Q · filed 2026-08-05 | $475.93M derived: sum of 3 quarters · filed 2026-08-05 | $592.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $148.13M 10-Q · filed 2026-05-06 | $281.75M derived: sum of 2 quarters · filed 2026-05-06 | $398.68M derived: sum of 3 quarters · filed 2026-05-06 | $530.19M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $133.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $250.55M derived: sum of 2 quarters · filed 2026-02-24 | $382.06M derived: sum of 3 quarters · filed 2026-02-24 | $476.64M 10-K · filed 2026-02-24 |
| 2024-09-30 | $116.94M 10-Q · filed 2025-11-04 | $248.44M derived: sum of 2 quarters · filed 2025-11-04 | $343.03M 10-Q · filed 2025-11-04 | $447.18M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $131.51M 10-Q · filed 2025-08-06 | $226.09M 10-Q · filed 2025-08-06 | $330.24M derived: sum of 3 quarters · filed 2026-02-24 | $427.67M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $94.59M 10-Q · filed 2025-05-07 | $198.74M derived: sum of 2 quarters · filed 2026-02-24 | $296.16M derived: sum of 3 quarters · filed 2026-02-24 | $368.85M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $104.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $201.57M derived: sum of 2 quarters · filed 2026-02-24 | $274.26M derived: sum of 3 quarters · filed 2026-02-24 | $332.34M 10-K · filed 2026-02-24 |
| 2023-09-30 | $97.42M 10-Q · filed 2024-11-05 | $170.11M derived: sum of 2 quarters · filed 2024-11-05 | $228.19M 10-Q · filed 2024-11-05 | $279.82M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $72.69M 10-Q · filed 2024-08-06 | $130.77M 10-Q · filed 2024-08-06 | $182.40M derived: sum of 3 quarters · filed 2025-02-25 | $230.08M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $58.08M 10-Q · filed 2024-05-08 | $109.71M derived: sum of 2 quarters · filed 2025-02-25 | $157.38M derived: sum of 3 quarters · filed 2025-02-25 | $195.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $51.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $99.31M derived: sum of 2 quarters · filed 2025-02-25 | $137.77M derived: sum of 3 quarters · filed 2025-02-25 | $169.45M 10-K · filed 2025-02-25 |
| 2022-09-30 | $47.68M 10-Q · filed 2023-11-06 | $86.15M derived: sum of 2 quarters · filed 2023-11-06 | $117.83M 10-Q · filed 2023-11-06 | $140.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $38.47M 10-Q · filed 2023-08-08 | $70.15M 10-Q · filed 2023-08-08 | $93.22M derived: sum of 3 quarters · filed 2024-02-27 | $113.65M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $31.68M 10-Q · filed 2023-05-08 | $54.75M derived: sum of 2 quarters · filed 2024-02-27 | $75.18M derived: sum of 3 quarters · filed 2024-02-27 | $92.83M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $23.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $43.50M derived: sum of 2 quarters · filed 2024-02-27 | $61.15M derived: sum of 3 quarters · filed 2024-02-27 | $78.41M 10-K · filed 2024-02-27 |
| 2021-09-30 | $20.43M 10-Q · filed 2022-11-07 | $38.08M derived: sum of 2 quarters · filed 2022-11-07 | $55.34M 10-Q · filed 2022-11-07 | $70.00M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $17.65M 10-Q · filed 2022-08-08 | $34.91M 10-Q · filed 2022-08-08 | $49.57M derived: sum of 3 quarters · filed 2022-08-08 | $65.98M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $17.26M 10-Q · filed 2022-05-09 | $31.92M derived: sum of 2 quarters · filed 2022-05-09 | $48.33M derived: sum of 3 quarters · filed 2022-05-09 | $66.51M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $14.66M 10-K · filed 2021-03-29 | $31.07M derived: sum of 2 quarters · filed 2021-11-10 | $49.25M derived: sum of 3 quarters · filed 2021-11-10 | $73.56M 10-K · filed 2023-02-27 |
| 2020-09-30 | $16.41M 10-Q · filed 2021-11-10 | $34.59M derived: sum of 2 quarters · filed 2021-11-10 | $58.90M 10-Q · filed 2021-11-10 | $72.28M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $18.18M 10-Q · filed 2021-08-11 | $42.49M 10-Q · filed 2021-08-11 | $55.87M derived: sum of 3 quarters · filed 2021-08-11 | $65.50M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $24.32M 10-Q · filed 2021-05-11 | $37.70M derived: sum of 2 quarters · filed 2021-05-11 | $47.33M derived: sum of 3 quarters · filed 2021-05-11 | $57.29M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $13.38M 10-K · filed 2021-03-29 | $23.01M derived: sum of 2 quarters · filed 2021-03-29 | $32.98M derived: sum of 3 quarters · filed 2021-03-29 | $45.61M 10-K · filed 2022-02-28 |
| 2019-09-30 | $9.63M 10-K · filed 2021-03-29 | $19.60M derived: sum of 2 quarters · filed 2021-03-29 | $32.23M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $9.97M 10-K · filed 2021-03-29 | $22.59M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $12.63M 10-K · filed 2021-03-29 | |||
| 2018-12-31 | $30.14M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |